PT-65

• Description:

  PT-65 is a potent and selective GSK3 PROTAC degrader with the highest degradation capacity of GSK3α (DC50= 28.3 nM) and GSK3β (DC50= 34.2 nM) in SH-SY5Y cells. PT-65 can be used in Alzheimer's disease research[1]. (Pink: GSK3 inhibitor (HY-15761) ; Black: linker; Blue: CRBN Ligand (HY-10984) )

• UNSPSC:

  12352005

• Target:

  GSK-3; PROTACs

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR; PROTAC; Stem Cell/Wnt

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pt-65.html

• Purity:

  99.48

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(N)N=CC(C2=CC=C(S(=O)(N3CCN(CCCCC4=CN(CCOCCOCCOCCOCCOCCNC5=CC=CC(C(N6C7C(NC(CC7)=O)=O)=O)=C5C6=O)N=N4)CC3)=O)C=C2)=N1)NC8=CC=CN=C8

• Molecular Formula:

  C51H63N13O12S

• Molecular Weight:

  1082.19

• References & Citations:

  [1]Qu L, et al. Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease. Eur J Med Chem. 2021 Dec 15;226:113889.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2721998-87-2]